EPPIC-Net EN21-01 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of 80 mg Daily of NRD135S.E1 Versus Placebo in Adult and Elderly Participants With Painful Diabetic Peripheral Neuropathy
Latest Information Update: 09 Apr 2025
At a glance
- Drugs NRD135S E1 (Primary)
- Indications Neuropathic pain
- Focus Adverse reactions; Therapeutic Use
- Acronyms EN21-01; SERENDIPITY-1
Most Recent Events
- 04 Apr 2025 Planned End Date changed from 31 Jan 2025 to 31 May 2025.
- 04 Apr 2025 Planned primary completion date changed from 31 Jan 2025 to 31 May 2025.
- 09 Aug 2024 Trial design presented at the 20th World Congress on Pain.